Výsledky vyhledávání

Energy-efficient Reactive and Predictive Connected Cruise Control

Autor: Minghao Shen, Robert Austin Dollar, Tamas G. Molnar, Chaozhe R. He, Ardalan Vahidi, Gábor Orosz

Publikováno v: IEEE Transactions on Intelligent Vehicles. :1-14

In this paper, we propose a framework for the longitudinal control of connected and automated vehicles traveling in mixed traffic consisting of connected and non-connected human-driven vehicles. Reactive and predictive controllers are proposed. React

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40043d7d3ca0a1d6761ebf1f32bf9b43
https://doi.org/10.1109/tiv.2023.3281763

Zobrazit plný text záznamu

Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma

Autor: Stephanie M. Woo, Alexandra V. Kimchy, Lynette M. Sequeira, Charles S. Dorris, Aiwu R. He, Amol S. Rangnekar

Publikováno v: Current Oncology. 29:9813-9825

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide, and its incidence has increased rapidly in the United States over the past two decades. Liver transplant is considered curative, but is not always possi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8559a8c188b8f38f75126d0746eda15
https://doi.org/10.3390/curroncol29120771

Zobrazit plný text záznamu

Plný text ve formátu HTML

Bacterial antibiotic resistance among cancer inpatients in China: 2016–20

Autor: Y Ju, K Liu, G Ma, B Zhu, H Wang, Z Hu, J Zhao, L Zhang, K Cui, X -R He, M Huang, Y Li, S Xu, Y Gao, H Liu, Z Zhuo, G Zhang, Z Guo, Y Ye, X Zhou, S Ma, Y Qiu, M Zhang, Y Tao, L Xian, W Xie, G Wang, Y Wang, C Wang, D -H Wang, K Yu

Publikováno v: QJM: An International Journal of Medicine. 116:213-220

Summary Background The incidence of infections among cancer patients is as high as 23.2–33.2% in China. However, the lack of information and data on the number of antibiotics used by cancer patients is an obstacle to implementing antibiotic managem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf5fc20be1a9e7fabe044c584ed040f1
https://doi.org/10.1093/qjmed/hcac244

Zobrazit plný text záznamu

Data from Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Autor: Ajay K. Gopal, Aron D. Thall, Bo Huang, Craig B. Davis, Ying Chen, Rossano Cesari, Michael J. Pishvaian, Shailender Bhatia, Ronald Levy, Toshihiko Doi, Aiwu R. He, Neil H. Segal

Purpose: Utomilumab (PF-05082566) is an agonistic mAb that engages the immune costimulatory molecule 4-1BB/CD137. In this first-in-human, phase I, open-label, multicenter, multiple-dose study (NCT01307267) we evaluated safety, tolerability, pharmacok

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::694989971a65a86e3429b40415deb7d4
https://doi.org/10.1158/1078-0432.c.6526034.v1

Zobrazit plný text záznamu

Supplementary Tables and Figures from Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Autor: Ajay K. Gopal, Aron D. Thall, Bo Huang, Craig B. Davis, Ying Chen, Rossano Cesari, Michael J. Pishvaian, Shailender Bhatia, Ronald Levy, Toshihiko Doi, Aiwu R. He, Neil H. Segal

Supplementary Table S1. Reason for treatment discontinuation Supplementary Table S2. Select laboratory abnormalities by maximum CTCAE grade Supplementary Table S3. Pharmacokinetic parameters for single-agent utomilumab (cycle 1) Supplementary Figure

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d08d9dbb5c451b56c61fbcb212dfdf52
https://doi.org/10.1158/1078-0432.22465484

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání